Scandion Oncology

Mindre end 1K følgere

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse25.6.2025, 15.00

Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025

Scandion Oncology

Selskabsmeddelelse25.6.2025, 12.00

Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market

Scandion Oncology

Selskabsmeddelelse27.3.2025, 15.00

Scandion Oncology Announces Results of Annual General Meeting

Scandion Oncology

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse12.3.2025, 12.10

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology

Selskabsmeddelelse12.3.2025, 12.05

Scandion Oncology - Annual Report 2024

Scandion Oncology

Selskabsmeddelelse12.3.2025, 12.00

Scandion Oncology – Q4 & yearend report 2024

Scandion Oncology

Selskabsmeddelelse26.2.2025, 17.40

Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks

Scandion Oncology

Selskabsmeddelelse26.2.2025, 17.35

Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report

Scandion Oncology

Selskabsmeddelelse26.2.2025, 17.30

Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting

Scandion Oncology

Selskabsmeddelelse13.1.2025, 06.00

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology

Selskabsmeddelelse20.11.2024, 16.30

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Scandion Oncology

Selskabsmeddelelse14.11.2024, 07.30

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology

Pressemeddelelse12.11.2024, 16.54

Redeye: Scandion Oncology Q3 2024 - Searching for a partner

Scandion Oncology

Scandion Oncology, Audiocast with teleconference, Q3'24

Videopræsentation11.11.2024, 08.00

Scandion Oncology, Audiocast with teleconference, Q3'24

Scandion Oncology

Selskabsmeddelelse11.11.2024, 06.00

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology

Pressemeddelelse5.11.2024, 16.00

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology

Selskabsmeddelelse4.11.2024, 07.30

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology

Selskabsmeddelelse31.10.2024, 07.30

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Selskabsmeddelelse30.10.2024, 16.00

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Pressemeddelelse29.8.2024, 10.26

Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope

Scandion Oncology

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.